PharmaEssentia (FRA:8Z1) Total Operating Expense: €253.3 Mil (TTM As of Dec. 2025)


FRA:8Z1 PharmaEssentia Corp FRA:8Z1
82 GF Score
Price €15.50
GF Value €14.50
! 6 Warning Signs
View Full Analysis

What is PharmaEssentia Total Operating Expense?

PharmaEssentia FRA:8Z1 82 Total Operating Expense is €253.3 Mil as of Dec. 2025. GuruFocus rates FRA:8Z1 with a GF Score™ of 82/100 and a GF Value™ of €14.50. The stock has 6 warning signs investors should review.

PharmaEssentia's Total Operating Expense for the three months ended in Dec. 2025 was €75.6 Mil. PharmaEssentia's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was €253.3 Mil.

PharmaEssentia Total Operating Expense Related Terms

PharmaEssentia Total Operating Expense Historical Data

* Premium members only.

The historical data trend for PharmaEssentia's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaEssentia Total Operating Expense Chart

PharmaEssentia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 98.87 126.20 188.04 199.99 245.76

PharmaEssentia Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 63.46 50.19 60.20 67.33 75.62
FRA:8Z1
82GF Score
PharmaEssentia Corp FRA:8Z1
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaEssentia Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €253.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €253.3 Mil mean?
PharmaEssentia (FRA:8Z1) has a Total Operating Expense of €253.3 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on PharmaEssentia and its competitors.
Is PharmaEssentia's Total Operating Expense too high?
PharmaEssentia's current Total Operating Expense is €253.3 Mil. Overall, PharmaEssentia has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does PharmaEssentia's Total Operating Expense compare to ZTS and UTHR?
PharmaEssentia's Total Operating Expense of €253.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on PharmaEssentia and its competitors. PharmaEssentia's current Total Operating Expense is €253.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaEssentia stock overvalued right now?
PharmaEssentia (FRA:8Z1) has a current Total Operating Expense of €253.3 Mil. The stock's GF Value™ is €14.50, compared to a current price of €15.50 — trading 6.9% above its estimated fair value. The current Total Operating Expense is €253.3 Mil. PharmaEssentia's overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For PharmaEssentia (FRA:8Z1), the current Total Operating Expense is €253.3 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PharmaEssentia (FRA:8Z1) Overvalued in 2026?

Based on GuruFocus' analysis, PharmaEssentia stock appears to be overvalued. The current stock price of €15.50 is trading 6.9% above its estimated GF Value™ of €14.50.

Key valuation signals for FRA:8Z1:

  • Total Operating Expense: €253.3 Mil
  • GF Value™: €14.50 vs. price of €15.50 (6.9% above fair value)
  • GF Score™: 82/100 with 6 warning signs

No single metric tells the full story. See the FRA:8Z1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PharmaEssentia Business Description

Other Exchanges 6446:Taiwan
Address 13th Floor, No.3, Park Street, Nangang District, Taipei, TWN, 115
PharmaEssentia Corp engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API and new drug patterns developments. Its products include BESREMi, Ropeginterferon alfa-2b, Ropeg + anti PD-1, PEG-IL-2, PEG-Cytokines, PD-1-IL-2v, NY-ESO-1 TCR-T, among others. It derives revenue from medicine products sales from contracts with customers.
82GF Score

Get the complete analysis for FRA:8Z1

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€15.50
Price
€14.50
GF Value